Cancer Risk Following ABO Incompatible Living Donor Kidney Transplantation (1)
Published Date:Sep 15 2013
Pubmed Central ID:PMC3759597
Funding:HHSN261201000037C/CA/NCI NIH HHS/United States
N01PC35143/CA/NCI NIH HHS/United States
U58 DP000805/DP/NCCDPHP CDC HHS/United States
U58 DP000817/DP/NCCDPHP CDC HHS/United States
HHSN261201000035C/CA/NCI NIH HHS/United States
HHSN261201000036C/CA/NCI NIH HHS/United States
N01PC35137/CA/NCI NIH HHS/United States
T32CA126607/CA/NCI NIH HHS/United States
U58 DP000807/DP/NCCDPHP CDC HHS/United States
U58 DP000808/DP/NCCDPHP CDC HHS/United States
T32 CA126607/CA/NCI NIH HHS/United States
N01PC35142/CA/NCI NIH HHS/United States
HHSN261201000035I/CA/NCI NIH HHS/United States
U58 DP000848/DP/NCCDPHP CDC HHS/United States
U58 DP000812/DP/NCCDPHP CDC HHS/United States
HHSN261201000024C/CA/NCI NIH HHS/United States
HHSN261201000034C/CA/NCI NIH HHS/United States
N01PC54405/CA/NCI NIH HHS/United States
U58 DP000832/DP/NCCDPHP CDC HHS/United States
N01PC35139/CA/NCI NIH HHS/United States
HHSN261201000026C/CA/NCI NIH HHS/United States
U58 DP000824/DP/NCCDPHP CDC HHS/United States
Recipients of ABO incompatible (ABOi) living donor kidney transplants often undergo more intense immunosuppression than their ABO compatible (ABOc) counterparts. It is unknown if this difference leads to higher cancer risk after transplantation. Single-center studies are too small, and lack adequate duration of follow-up, to answer this question.
We identified 318 ABOi recipients in the Cancer Transplant Match Study, a national linkage between the Scientific Registry of Transplant Recipients and population-based U.S. cancer registries. Seven cancers (non-Hodgkin lymphoma, Merkel cell carcinoma, gastric adenocarcinoma, hepatocellular carcinoma, thyroid cancer, pancreatic cancer, and testicular cancer) were identified among ABOi recipients. We then matched ABOi recipients to ABOc controls by age, gender, race, HLA mismatch, retransplantation, and transplant year.
There was no demonstrable association between ABOi and cancer in unadjusted incidence rate ratio (IRR 0.83, 95% CI 0.33–1.71, p=0.3) or matched control analysis (IRR 0.99, 95% CI 0.38–2.23, p=0.5).
To the extent that could be determined in this registry study, current desensitization protocols are not associated with increased risk of cancer after transplantation.
You May Also Like: